G
Gérard Zalcman
Researcher at University of Paris
Publications - 111
Citations - 2628
Gérard Zalcman is an academic researcher from University of Paris. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 19, co-authored 98 publications receiving 1656 citations. Previous affiliations of Gérard Zalcman include PSL Research University & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Paul Baas,Arnaud Scherpereel,Anna K. Nowak,Nobukazu Fujimoto,Solange Peters,Anne S. Tsao,Aaron S. Mansfield,Sanjay Popat,Thierry Jahan,Scott J. Antonia,Youssef Oulkhouir,Yolanda Bautista,Robin Cornelissen,Laurent Greillier,Francesco Grossi,Dariusz M. Kowalski,Jerónimo Rodríguez-Cid,Praveen Aanur,Abderrahim Oukessou,Christine Baudelet,Gérard Zalcman +20 more
TL;DR: The CheckMate 743 trial as mentioned in this paper showed that nivolumab plus ipilimumab significantly improved overall survival compared to standard-of-care chemotherapy for non-small-cell lung cancer.
Journal ArticleDOI
Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry
Oliver Gautschi,Julie Milia,Thomas Filleron,Juergen Wolf,David P. Carbone,Dwight H. Owen,R. Camidge,Vignhesh Narayanan,Robert C. Doebele,Benjamin Besse,Jordi Remon-Masip,Pasi A. Jänne,Mark M. Awad,Nir Peled,Chul Cho Byoung,Daniel D. Karp,Michael Van Den Heuvel,Heather A. Wakelee,Joel W. Neal,Tony Mok,James Chih-Hsin Yang,Sai-Hong Ignatius Ou,Georg Pall,Patrizia Froesch,Gérard Zalcman,David R. Gandara,Jonathan W. Riess,Vamsidhar Velcheti,Kristin Zeidler,Joachim Diebold,Martin Früh,Sebastian Michels,Isabelle Monnet,Sanjay Popat,Rafael Rosell,Niki Karachaliou,Sacha I. Rothschild,Jin-Yuan Shih,Arne Warth,Thomas Muley,Florian Cabillic,Julien Mazieres,Alexander Drilon +42 more
TL;DR: The results of an international registry of patients with RET-rearranged NSCLCs, providing the largest data set, to the authors' knowledge, on outcomes of RET-directed therapy thus far, are presented.
Journal Article
Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.
R. Lubin,Beata Schlichtholz,Bengoufa D,Gérard Zalcman,Jean Trédaniel,A. Hirsch,C.Caron de Fromentel,Claude Preudhomme,Pierre Fenaux,Georges Fournier,Philippe Mangin,Pierre Laurent-Puig,Gilles Pelletier,M. Schlumberger,François Desgrandchamps,A. Le Duc,Jean-Philippe Peyrat,Nicolas Janin,B. Bressac,Thierry Soussi +19 more
TL;DR: It is proposed that the p53 humoral response is the result of a self-immunization process which is itself the consequence of p53 protein accumulation in tumor cells.
Journal ArticleDOI
Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein.
TL;DR: It is suggested that p53 antibodies occur via a self-immunisation process that is the consequence of p53 accumulation in tumour cells, as well as in patients without detected malignant disease.
Journal ArticleDOI
RhoGDI-3 Is a New GDP Dissociation Inhibitor (GDI) IDENTIFICATION OF A NON-CYTOSOLIC GDI PROTEIN INTERACTING WITH THE SMALL GTP-BINDING PROTEINS RhoB AND RhoG
Gérard Zalcman,Violaine Closson,Jacques Camonis,Nicole Honoré,Marie-Françoise Rousseau-Merck,Armand Tavitian,Birgitta Olofsson +6 more
TL;DR: This work has reported that the transient expression of the endogenous RhoB protein is regulated during the cell cycle, contrasting with the permanent RhoA protein expression, and identified a new mouse Rho GDP dissociation inhibitor, referenced as RhoGDI-3.